

Tissue Regenix Group PLC

05:53 23 May 2016

Tissue Regenix eyeing European market

Regenerative medical technology firm Tissue Regenix Group PLC (LON:TRX) is eyeing a busy year ahead as it expects to bring its dCell technology to the European market within the coming year.

The firm on May 23 reported increased revenue and an increased balance sheet in its financial year to end January, 2016.

The firm's technology removes cellular material from animal and human tissue leaving a 'scaffold' which can then be used to repair diseased or worn out body parts.

Chief executive Antony Odell told investors: "During the year to January, 31, Tissue made significant progress both in the commercialisation and regulatory pathways across all of our key focus areas."

Regeneration is revolutionising treatments

With an ageing population and increasing participation in sports, the benefits of new methods of treatments that Tissue offers are becoming increasingly clear.

The firm has said the market is expected to reach US\$11.5bn by 2022.

It is currently involved in three clinical areas - woundcare, where it has developed DermaPure, which is specifically useful in diabetes, and expects to launch SurgiPure, for the repair of hernias or body wall defects, in the second half of its accounting year.

It also has an orthopaedic side to the business and a cardiac one, where it hopes to bring its heart valves to European patients in the near future through a joint venture.

Dermapure in the US beats expectations

Its woundcare product DermaPure surpassed \$1mln of sales in the US, exceeding the group's expectations.

The group's orthopaedic clinical trials are currently ongoing, for both the OrthoPure XM and XT (porcine products), and it anticipate that it will have CE mark (for European commercialisation) approval by early 2017.

"We have also strengthened our senior management team by appointing a VP of Orthopedics for North America, who will be key to guiding our entry into this market over the coming years with both our porcine products and human tissue applications," said Odell.


In final results, the group also highlighted its joint venture in Germany, GBM-V, allowing it to bring the dCELL human tissue applications to a wider European market.

"Also, allowing us to grant for the first time the dCELL heart valve licence and to begin commercialising DermaPure

Price: 0.55

Market Cap: £38.68 m

1 Year Share Price Graph



December 2019 June 2020 November 20

Share Information

Code: TRX

Listing: AIM

52 week High Low
1.76489 0.275

Sector: Pharma & Biotech

Website: www.tissuregenix.com

Company Synopsis:

TISSUE REGENIX GROUP is a pioneering, international medical technology company, focusing on the development of regenerative products utilising our two platform technologies, dCELL®, addressing soft tissue needs, and BioRinse™, providing inductive bone allografts. We are helping to transform the treatment of patients in three key areas: BioSurgery, Orthopaedics & Dental and Cardiac.

action@proactiveinvestors.com

outside the US," said the chief executive.

"Our momentum has accelerated since year end, with further Medicare coverage for DermaPure, and 510(k) market clearance from the FDA for medical device SurgiPure XD, the first approval for a dCELL application under this regulatory body."

In March, US broker Jefferies said it expected further Dermapure sales in the US through 2016/2017.

But it reckoned the orthopedic products - OrthoPure - will provide the next leg of growth and will provide meaningful revenues from the first half of the 2017/18 year.

More than 1.5m people suffer meniscal injuries in the US and EU alone, of which OrthoPure XM would likely target 300,000, it said.

"The other key franchise in the orthopedics portfolio is OrthoPure XT (ACL repair), for which the trial commenced in Dec-15 with first results likely in 1H16/17. The company is on target to launch the human tissue orthopedic products in the US by end-FY16/17," said the broker.

It added "We estimate FY17 Dermapure/ Surgipure sales of \$9m/\$0.6m, with \$2.9m from Orthopure by FY18. We continue to view orthopedics as the greater LT value driver and are encouraged by progress to date."

Jefferies raised the price target to 37p from 36p - which is more than double the current shareprice of 17.75p.

Revenue in the year gone grew to £0.8m from £0.1m the year before, while the cash balance at year end stood at £19.9m (£10.3m).

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Tissue Regenix Group PLC named herein, including the promotion by the Company of Tissue Regenix Group PLC in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).